Markman / Cohen Integrative Oncology

Incorporating Complementary Medicine into Conventional Cancer Care
1. Auflage 2008
ISBN: 978-1-59745-183-3
Verlag: Humana Press
Format: PDF
Kopierschutz: 1 - PDF Watermark

E-Book, Englisch, 216 Seiten

Reihe: Current Clinical Oncology

Integrative medicine strives to incorporate the best of complementary and conventional modalities. This book details integrative oncology, a nascent field building a rigorous evidenced-based clinical medicine, research, and educational foundation. It examines five prestigious, comprehensive cancer centers based in the US, covering how these centers started their programs, what they are currently doing, and recommendations for starting integrative medicine clinics. The book also discusses the potential harm of alternative and complementary medicine, legal issues, and how to communicate with patients.

Autoren/Hrsg.

Markman, Maurie

Cohen, Lorenzo

Inhaltsverzeichnis

1;Preface;7
2;Contents;8
3;Contributors;10
4;Integrative Oncology Overview;13
4.1;Introduction;14
4.2;A Word of Caution;19
4.2.1;Contents;19
4.2.2;2.1 Risk of “Harm” Associated with “Non-conventional” Approaches to Cancer Management;20
4.2.3;2.2 Direct Harmful Effects of Non-traditional Strategies;21
4.2.4;2.3 Conclusion;22
4.2.5;References;22
4.3;Using Legal and Ethical Principles to Guide Clinical Decision Making in Complementary/ Integrative Cancer Medicine;24
4.3.1;Contents;24
4.3.2;3.1 Introduction;24
4.3.3;3.2 Major Applicable Legal Rules;25
4.3.4;3.2.1 Licensure and Credentialing;26
4.3.5;3.2.2 Scope of Practice;27
4.3.6;3.2.3 Malpractice;28
4.3.7;3.2.4 Professional Discipline, Third-Party Reimbursement, and Healthcare Fraud;28
4.3.8;3.3 Malpractice Issues in Greater Detail;29
4.3.9;3.3.1 Misdiagnosis in Cancer Medicine;30
4.3.10;3.3.2 Failure to Treat in Cancer Medicine;30
4.3.11;3.3.3 Informed Consent in Cancer Medicine;33
4.3.12;3.3.4 Referral Liability in Cancer Medicine;34
4.3.13;3.4 SomeWays to Help Manage Liability Risks;35
4.3.14;3.5 The Federation of State Medical Board Guidelines for Integrative Medicine;36
4.3.15;3.6 A Broader Ethical Analysis;37
4.3.16;3.7 Conclusion;39
4.3.17;References1;40
4.4;Communicating with Patients about the Use of Complementary and Integrative Medicine in Cancer Care;42
4.4.1;Contents;42
4.4.2;4.1 Introduction;43
4.4.3;4.2 Communication in Cancer Care;44
4.4.4;4.2.1 The Patient’s Perspective;46
4.4.5;4.2.2 The Physician’s Perspective;47
4.4.6;4.3 Communication Between Physicians and CIM Practitioners;48
4.4.7;4.3.1 Building the Bridge of Communication;49
4.4.8;4.3.2 A Suggested Approach;50
4.4.9;4.4 Conclusion;52
4.4.10;References;52
5;Integrative Oncology Programs at National Cancer Institute Comprehensive Cancer Centers;56
5.1;The Integrative Medicine Program at The University of Texas M. D. Anderson Cancer Center;57
5.1.1;Contents;57
5.1.2;5.1 Combining the Best Approaches from Conventional and Complementary Medicine;58
5.1.3;5.2 Clinical Delivery 5.2.1 Beginnings;58
5.1.4;5.2.2 Developing our Mission and Scope;59
5.1.5;5.2.3 Screening and Processing Program Proposals;61
5.1.6;5.2.4 Credentialing Process, Programs, and Services;61
5.1.7;5.2.5 Registration and Screening;63
5.1.8;5.2.6 Funding;64
5.1.9;5.2.7 Other Key Operational Areas;64
5.1.10;5.3 Education;65
5.1.11;5.3.1 Programs;65
5.1.12;5.3.2 Internal Collaborations;70
5.1.13;5.3.3 Program Evaluation and Assessment;70
5.1.14;5.4 Marketing;71
5.1.15;5.5 Research;72
5.1.16;5.6 Summary;73
5.1.17;References;73
5.2;The Integrative Medicine Service at Memorial Sloan- Kettering Cancer Center;74
5.2.1;Contents;74
5.2.2;6.1 Introduction;74
5.2.3;6.1.1 Emergence of the MSKCC Integrative Medicine Service;75
5.2.4;Memorial Sloan-Kettering Cancer Center Integrative Medicine Service;76
5.2.5;6.1.2 Role of Integrative Medicine at MSKCC;76
5.2.6;6.2 Clinical Services;77
5.2.7;6.3 Therapies Offered and Related Research;79
5.2.8;6.3.1 Touch Therapy;79
5.2.9;6.3.2 Music Therapy;80
5.2.10;6.3.3 Acupuncture;81
5.2.11;6.3.4 Mind-Body Therapies;82
5.2.12;6.3.5 Movement/Fitness Program;82
5.2.13;6.3.6 Nutrition;83
5.2.14;6.3.7 Immune-Modulating Botanicals Research;83
5.2.15;6.3.8 Education and Training;84
5.2.16;6.3.9 Information Program: AboutHerbs Web site ( www. mskcc. org/ aboutherbs);84
5.2.17;6.4 Summary;85
5.2.18;References;85
5.3;Integrative Oncology—Leonard P. Zakim Center;86
5.3.1;Contents;86
5.3.2;7.1 Introduction 7.1.1 Development of the Concept of Integrative Oncology at DFCI and First Steps;87
5.3.3;7.2 Mission Statement;88
5.3.4;7.2.1 Operational Development;88
5.3.5;7.3 Policies and Procedures;90
5.3.6;7.4 Documentation and Scheduling of Integrative Therapies;96
5.3.7;7.5 Zakim Center Collaborations;99
5.3.8;7.6 Growth of the Zakim Center;100
5.3.9;7.7 Financials;102
5.3.10;7.8 Creating an Integrative Education Program for Patients and Families, Physicians, Nurses, and Researchers;104
5.3.11;7.8.1 Professional Education;106
5.3.12;7.9 Development of a Research Program;107
5.3.13;7.10 Concluding Thoughts;109
5.3.14;References;110
5.4;The Johns Hopkins Complementary and Integrative Medicine Service;111
5.4.1;Contents;111
5.4.2;8.1 Introduction;112
5.4.3;8.2 Clinical Service Initial Stage Development Process 8.2.1 Overview of the Institution;112
5.4.4;8.2.2 Early Interest and Planning;112
5.4.5;8.2.3 Creation of a Johns Hopkins Research CAM Center;113
5.4.6;8.2.4 Establish an Advisory Board;113
5.4.7;8.2.5 Search for and Hire a Program Coordinator to Create the Program;113
5.4.8;8.3 Practical Aspects in Planning a Complementary and Integrative Medicine Service 8.3.1 Establish a Steering Committee;114
5.4.9;8.3.2 Survey Other Institutions;114
5.4.10;8.3.3 Survey Current Hopkins Employees to Identify Qualified CAM Practitioners;114
5.4.11;8.3.4 Conduct Administrative Meetings with Representatives from Key Departments;115
5.4.12;8.3.5 Key Issues Discussed in the Initial Planning Stages;115
5.4.13;8.4 Services Now Being Provided 8.4.1 Acupuncture;116
5.4.14;8.4.2 Massage Therapy;118
5.4.15;8.4.3 Mind-Body Class;119
5.4.16;8.4.4 Integrative Medicine Consult Service;119
5.4.17;8.5 Administration of the CIM Service 8.5.1 Credentialing;119
5.4.18;8.5.2 Policies/Procedures;120
5.4.19;8.5.3 Job Descriptions;120
5.4.20;8.5.4 Developing Clinical Forms;120
5.4.21;8.5.5 Liaisons;121
5.4.22;8.6 Financial Aspects 8.6.1 Negotiating Billing Procedures;121
5.4.23;8.6.2 Space;121
5.4.24;8.6.3 Equipment;122
5.4.25;8.6.4 Scheduling;122
5.4.26;8.6.5 Referrals;122
5.4.27;8.6.6 Marketing;123
5.4.28;8.7 Education Programs;123
5.4.29;8.8 Case Study;124
5.4.30;8.9 Challenges Faced by the Complementary and Integrative Medicine Service;125
5.4.31;8.10 Conclusions/Summary;126
5.4.32;References;127
5.5;Integrative Oncology at Mayo Clinic;128
5.5.1;Contents;128
5.5.2;9.1 Research in Integrative Medicine and Oncology;129
5.5.3;9.1.1 Hot Flashes;130
5.5.4;9.1.2 Pain;133
5.5.5;9.1.3 Anorexia/Cachexia;133
5.5.6;9.1.4 Treatment for Advanced Cancer;135
5.5.7;9.2 Research Summary;136
5.5.8;9.2.1 Education;136
5.5.9;9.2.2 Patient Care;138
5.5.10;9.3 Conclusion;139
5.5.11;References;139
6;The Research;141
6.1;Mind–Body Research in Cancer;142
6.1.1;Contents;142
6.1.2;10.1 Utilization of Mind-Body Practices;143
6.1.3;10.2 Mind-Body Connection;144
6.1.4;10.3 Mind-Body Research at M. D. Anderson;146
6.1.5;10.3.1 Background on Yoga, Meditation, and Qigong;146
6.1.6;10.3.2 M. D. Anderson’s Past and Ongoing Studies of Yoga, Meditation, and Qigong;151
6.1.7;10.4 Limitations of Mind-Body Research;156
6.1.8;References;157
6.2;Herbs and Other Botanicals: Interactions with Pharmaceuticals;164
6.2.1;Contents;164
6.2.2;11.1 Introduction;164
6.2.3;11.2 Definitions;165
6.2.4;11.3 Cancer Patient Use of Herbal Supplements;165
6.2.5;11.4 Botanicals Research 11.4.1 Huanglian — A Phase I Study of the Chinese Herb Huanglian ( Coptis chinensis) in Patients with Advanced Solid Tumors;166
6.2.6;11.4.2 Jin Fu Kang —Safety and Pharmacokinetic Study of Jin Fu Kang in Combination with Docetaxel for Patients with Non- Small Cell Lung Cancer.;169
6.2.7;11.4.3 Maitake—A Phase I/II study of Maitake Extract in Breast cancer Patients;173
6.2.8;11.4.4 Sho-Saiko-To—Sho-Saiko-To for Patients with Chronic Hepatitis C Who are Intolerant to or Have Contraindication to Interferon- Based Therapy: A Phase II Study;175
6.2.9;11.4.5 Problems Associated with Botanicals Research;178
6.2.10;References;179
6.3;Acupuncture in Cancer Care at Dana-Farber Cancer Institute;184
6.3.1;Contents;184
6.3.2;12.1 Overview and Background;185
6.3.3;12.1.1 Acupuncture at DFCI;185
6.3.4;12.1.2 Documentation;187
6.3.5;12.1.3 Developing Standardized Acupuncture Protocols;188
6.3.6;12.2 Oncology Acupuncture, a New Medical Specialty?;188
6.3.7;12.2.1 Requirements and Challenges for an Oncology Acupuncturist;188
6.3.8;12.2.2 Potential Sources of Oncology Acupuncturists;189
6.3.9;12.3 Clinical Applications for Common Conditions in Cancer Care;190
6.3.10;12.3.1 Acupuncture for Chemotherapy-Induced Nausea/Vomiting;191
6.3.11;12.3.2 Acupuncture for Radiotherapy-Induced Xerostomia;191
6.3.12;12.3.3 Acupuncture for Post-Chemotherapy-Related Fatigue;192
6.3.13;12.3.4 Acupuncture for Chemotherapy-Related Neuropathy;192
6.3.14;12.3.5 Acupuncture for Cancer Pain;192
6.3.15;12.3.6 Acupuncture for Insomnia and Anxiety;193
6.3.16;12.3.7 Acupuncture for Other Clinical Issues;193
6.3.17;12.4 Contraindications and Precautions in Acupuncture in Cancer Care 12.4.1 Neutropenia;193
6.3.18;12.4.2 Thrombocytopenia;194
6.3.19;12.4.3 Anticoagulants;194
6.3.20;12.4.4 Metastatic Sites;194
6.3.21;12.5 Acupuncture Use Inside a Cancer Center 12.5.1 Daily Clinical Pathways of Acupuncture Care;194
6.3.22;12.5.2 Pre-Clinical Time Preparations;195
6.3.23;12.5.3 Record Review Prior To Treatment;196
6.3.24;12.5.4 New Patients;197
6.3.25;12.5.5 History Taking;197
6.3.26;12.5.6 Clinical Referral Paths of Acupuncture Care;199
6.3.27;References;201
6.4;Acupuncture for the Side Effects of Cancer Treatments;203
6.4.1;Contents;203
6.4.2;13.1 Introduction;203
6.4.3;13.2 Side Effects of Cancer Treatment 13.2.1 Oral Mucositis;204
6.4.4;13.2.2 Peripheral Neuropathy;207
6.4.5;13.2.3 Nausea/Vomiting;208
6.4.6;13.2.4 Fatigue;209
6.4.7;13.3 Conclusion and Summary;210
6.4.8;References;210
7;Index;214